PTGS2 and neoplasm: Treatment with celecoxib has been shown to act on multiple targets and pathways in cancer cells, including proliferation, apoptosis, angiogenesis, invasion and tumor-induced immune suppression via COX-2 dependent and independent mechanisms [21, 25, 26].